Embolization Particle Market-Rising Prevalence of Cancer & Demand for New Diagnostic Techniques Accelerate the Growth of the Market

Pune, India, January, 2018/MRFR Press Release/- Market Research Future published a Cooked research report on “Global  Embolization Particle Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Embolization Particle Market-Overview

Embolization is a minimally invasive therapy to stop bleeding and blood flow to a tumour in order to shrink it or for removal. In this procedure some embolized particles or substances are injected into the vein of the patient to block or reduce the blood flow to cancer cells. Embolization is one of the best options for patients with tumours that cannot be removed by surgery. Embolization does reduce some of the blood supply to the normal liver tissue, so it may not be a good option for some patients whose liver has been damaged by diseases such as hepatitis or cirrhosis.

Technological advancement and rising demand for diagnostics and treatment options for cancer are key players in the market. Moreover, increasing number of patients with various oncological conditions have increased the demand for different embolization particles in the market. Furthermore, in the treatment of various types of cancer such as liver cancer, brain cancer, lung cancer embolization particle are used. Developing regions provide ample opportunities for the growth of the embolization particle market.

Key players in the Embolization Particle market                                                                    

Boston Scientific Corporation, Guerbet, BTG International Ltd, Medtronics, Sirtex, Terumo, and Merit Medical are the key players in the global embolization particle market.

Access Complete Report @ https://www.marketresearchfuture.com/reports/embolization-particle-market-4815

Key developments

Strategic approaches adopted help the major players to sustain their growth in the market and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.

Integrate Embolization Particle

July, 2016: Integrated Embolization Particle received clearance from the FDA for its nuvis Single-Use Arthroscope. It is the first FDA-approved disposable rigid endoscope.

In February, 2016: Integrated Embolization Particle demonstrated its nuvis Single-Use Arthroscope at the 2016 American Academy of Orthopaedic Surgeons (AAOS) Meeting in Orlando, USA.

Sirtex:

September, 2016: Sirtex expanded in Europe and included health professionals from United Kingdom, Belgium, Spain and Italy

September, 2014: Sirtex Medical Inc. expanded business into Brazil, and experienced record growth

March, 2014: Sirtex and Guerbet collaborated on clinical studies in primary and secondary liver cancer

Boston Scientific Corporation

March, 2017: Boston Scientific Corporation Announced Agreement to Acquire Symetisenergy to reduce the amount of excess smooth muscle tissue in the airways.

November, 2015: Boston Scientific Corporation acquired interventional radiology business of CeloNova Biosciences

Guerbet

November, 2015: Guerbet completed the acquisition of Mallinckrodt’s Contrast Media and Delivery Systems

September, 2014: Guerbet received the approval from French regulatory authorities for the use of its Lipiodol Ultra-Fluid product for chemoembolization of hepatocellular carcinoma

BTG International Ltd

February, 2017  BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

October, 2017: First patient treated with microscopic beads pre-loaded with a targeted cancer drug and visible on CT scans

April, 2016: BTG announced the United States launch of LC Bead LUMI, ground-breaking radiopaque embolic bead

October, 2015: BTG and MIRADA Collaborated to develop Dosimetry Software Solutions to Optimise Radioembolisation Therapy in Interventional Oncology

Merit Medical:

June, 2017: Merit Medical’s Embosphere Microspheres received FDA 513(f)(2) (de novo) classification for prostatic artery embolization indication

February, 2017: Merit Medical acquired products from Argon Medical Devices and Catheter Connections, Inc.

Global Embolization Particle Market

North America dominates the Americas embolization particle market. North America is further segmented into the U.S. and Canada. The U.S. holds the major share of the market owing to a well-developed economy, rising prevalence of cancer, and increasing government support for research & development. South America is still a developing region in terms of the infrastructure and technology.

According to American Cancer Society, (2017) About 222,500 new cases of lung cancer (116,990 in men and 105,510 in women) and about 155,870 deaths from lung cancer (84,590 in men and 71,280 in women) in U.S. As per American Cancer Society’s (2017) estimated About 63,990 new cases of kidney cancer (40,610 in men and 23,380 in women) will occur and about 14,400 people (9,470 men and 4,930 women) will die from this disease. According to the WHO estimates, brain associated disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.